The test, created by Des Plaines, Ill.-based Abbott Molecular, is designed to distinguish between the hepatitis C virus genotypes 1, 1a, 1b, 2, 3, 4 and 5. The test is expected to help improve patient outcomes by helping physicians to indentify the type of hepatitis C a patient has and choose the appropriate drug therapy.
More Articles on Gastroenterology:
International Surgery Journal Appoints Dr. Rajiv Datta to Editorial Board
Polyclinic Surgery Center Selects ProVation Medical Software
12 Statistics on GI Revenue per Case by Geographic Location
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.